Expression regulation and function of PD-1 and PD-L1 in T lymphoma cells

Liu, Maria Y.; Klement, John D.; Langan, Candace; Riggelen, Jan van; Liu, Kebin

doi:10.1016/j.cellimm.2021.104397

Cited by 7 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IFN-γ is a key inducer of PD-L1 expression in both M1 macrophages and cancer cells ( 122 , 123 ). PD-1 receptor is a repressive receptor present on the cell surface of activated T cells ( 124 ). The PD-1/PD-L1 axis suppresses the activation of immune cells and represents a momentous mechanism exploited by cancer cells to evade antitumor immunity ( 125 ).…”

Section: Tumor Immunitymentioning

confidence: 99%

The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes

et al. 2023

View full text Add to dashboard Cite

The gastrointestinal tract is inhabited by trillions of commensal microorganisms that constitute the gut microbiota. As a main metabolic organ, the gut microbiota has co-evolved in a symbiotic relationship with its host, contributing to physiological homeostasis. Recent advances have provided mechanistic insights into the dual role of the gut microbiota in cancer pathogenesis. Particularly, compelling evidence indicates that the gut microbiota exerts regulatory effects on the host immune system to fight against cancer development. Some microbiota-derived metabolites have been suggested as potential activators of antitumor immunity. On the contrary, the disequilibrium of intestinal microbial communities, a condition termed dysbiosis, can induce cancer development. The altered gut microbiota reprograms the hostile tumor microenvironment (TME), thus allowing cancer cells to avoid immunosurvelliance. Furthermore, the gut microbiota has been associated with the effects and complications of cancer therapy given its prominent immunoregulatory properties. Therapeutic measures that aim to manipulate the interplay between the gut microbiota and tumor immunity may bring new breakthroughs in cancer treatment. Herein, we provide a comprehensive update on the evidence for the implication of the gut microbiota in immune-oncology and discuss the fundamental mechanisms underlying the influence of intestinal microbial communities on systemic cancer therapy, in order to provide important clues toward improving treatment outcomes in cancer patients.

show abstract

Section: Tumor Immunitymentioning

confidence: 99%

The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The presence of PD-1 (mRNA or protein) is seldom detected and appears only after a period of stimulation ( 37 ). Activation of lymphocyte B cell receptors or T cell receptors is often associated with an increase in PD-1 expression ( 38 , 39 ).…”

Section: Pd-1 and Pd-l Expression And Structurementioning

confidence: 99%

Role of regulation of PD-1 and PD-L1 expression in sepsis

Zhang

Yu-Jing

2023

Front. Immunol.

View full text Add to dashboard Cite

Long term immunosuppression is problematic during sepsis. The PD-1 and PD-L1 immune checkpoint proteins have potent immunosuppressive functions. Recent studies have revealed several features of PD-1 and PD-L1 and their roles in sepsis. Here, we summarize the overall findings of PD-1 and PD-L1 by first reviewing the biological features of PD-1 and PD-L1 and then discussing the mechanisms that control the expression of PD-1 and PD-L1. We then review the functions of PD-1 and PD-L1 in physiological settings and further discuss PD-1 and PD-L1 in sepsis, including their involvement in several sepsis-related processes and their potential therapeutic relevance in sepsis. In general, PD-1 and PD-L1 have critical roles in sepsis, indicating that their regulation may be a potential therapeutic target for sepsis.

show abstract

“…Thus, PD1 can regulate the proliferation of lung cancer cells, but whether it has a positive or negative regulatory effect needs to be further verified. Additionally, PD1 + PD-L1 + T lymphoma cells promote tumor growth by activating TCR signaling [ 18 ].…”

Section: Pd1 and Pd-l1mentioning

confidence: 99%

The Proliferative Role of Immune Checkpoints in Tumors: Double Regulation

Tang

Luo

Xiong

et al. 2022

Cancers

View full text Add to dashboard Cite

Cancer remains a serious social health problem, and immunotherapy has become the major treatments in tumor treatment. Additionally, improving the efficiency and safety of treatment is necessary. Further, more therapy targets are warranted for future tumor treatments. In this review, in addition to examining the currently recognized role of immune regulation, we focus on the proliferative role of 15 immune checkpoints in various tumors, including PD1, PD-L1, FGL1, CD155, CD47, SIRPα, CD276, IDO1, SIGLEC-15, TIM3, Galectin-9, CD70, CD27, 4-1BBL, and HVEM. We managed to conclude that various immune checkpoints such as PD1/PD-L1, FGL1, CD155, CD47/SIRPα, CD276, and SIGLEC-15 all regulate the cell cycle, and specifically through Cyclin D1 regulation. Furthermore, a variety of signal pathways engage in proliferation regulation, such as P13K, AKT, mTOR, and NK-κB, which are also the most common pathways involved in the regulation of immune checkpoint proliferation. Currently, only PD1/PD-L1, CD47/SIRPα, TIM3/Galectin-9, and CD70/CD27 checkpoints have been shown to interact with each other to regulate tumor proliferation in pairs. However, for other immune checkpoints, the role of their receptors or ligands in tumor proliferation regulation is still unknown, and we consider the enormous potential in this area. An increasing number of studies have validated the various role of immune checkpoints in tumors, and based on this literature review, we found that most of the immune checkpoints play a dual regulatory role in immunity and proliferation. Therefore, the related pathways in proliferation regulation can served the role of therapy targets in tumor therapy. Further, great potential is displayed by IDO1, SIGLEC-15, 4-1BBL, and HVEM in tumor proliferation regulation, which may become novel therapy targets in tumor treatment.

show abstract

Expression regulation and function of PD-1 and PD-L1 in T lymphoma cells

Cited by 7 publications

References 18 publications

The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes

The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes

Role of regulation of PD-1 and PD-L1 expression in sepsis

The Proliferative Role of Immune Checkpoints in Tumors: Double Regulation

Contact Info

Product

Resources

About